Reading BBIO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BBIO free→Reading BBIO? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track BBIO free→QuarterlyIQ Insights · BBIO
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Termination of a Material Definitive Agreement On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026. Forward-Looking Statements To the extent that statements in this Current Report on Form 8-K are not strictly historical,…
Entry Into a Material Definitive Agreement. On May 7, 2026, BridgeBio Pharma, Inc. (the “Company”) filed a registration statement on Form S-3ASR (File No.: 333-295678, the “Registration Statement”) under Rule 415 of the Securities Act of 1933, as amended (the “Securities Act”) with the Securities and Exchange Commission . In addition, on May 7, 2026, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC (“Goldman Sachs”) and Leerink Partners…
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Other Events. On May 6, 2026, the Board of Directors of the Company approved a stock repurchase program pursuant to which the Company may purchase up to $500 million of the Company’s outstanding common stock. Stock repurchases under the program may be made from time to time, in the open market, in privately negotiated transactions and otherwise, at the discretion of management of the Company and in accordance with applicable federal securities laws, including Rule 10b-18 of the Exchange Act,…
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
BridgeBio’s offering and sale of the Notes to the Initial Purchasers was made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. BridgeBio relied on this exemption from registration based in part on representations made by the Initial Purchasers in the purchase agreement for the Notes, including that the Initial Purchasers would only offer, sell or deliver the Notes to persons whom they believed to be qualified institutional buyers within the mea…
Entry into a Material Definitive Agreement. Indenture and Notes On January 21, 2026, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $632.5 million aggregate principal amount of its 0.75% Convertible Senior Notes due 2033 (the “Notes”), pursuant to an Indenture dated January 21, 2026 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) pursua…
Other Events. On January 14, 2026, BridgeBio issued a press release announcing its intention to offer the Notes. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. On January 15, 2026, BridgeBio issued a press release announcing the pricing of the Notes. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. Share Repurchases BridgeBio used approximately $82.5 million of cash on hand to repurchase…
Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in
Results of Operations and Financial Condition. On January 12, 2026, BridgeBio Pharma, Inc., or the Company, issued a press release that contains certain preliminary financial information as of and for the quarter and fiscal year ended December 31, 2025. Specifically, the press release states that the Company estimates it had approximately $587.5 million of cash, cash equivalents and marketable securities as of December 31, 2025 and $146.0 million and $362.4 million in net product revenue for…
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth in
Entry into a Material Definitive Agreement Royalty Interest Purchase and Sale Agreement On June 27, 2025 (the “Closing Date”), BridgeBio Pharma, Inc. (the “Company”) and its subsidiary Eidos Therapeutics, Inc. (“Eidos”) entered into a Royalty Interest Purchase and Sale Agreement (the “Purchase Agreement”) with Acoramidis Royalty SPV, LP (“ARS”), as a purchaser and the purchaser representative (in such capacity, the “Purchaser Representative”), and LSI Financing Fund, LP, as a purchaser (toget…
Material Modification to Rights of Security Holders. As further described under
of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. The employment of Brian C. Stephenson, the Chief Financial Officer of BridgeBio Pharma, Inc. (the “Company”), ended on March 17, 2025 (the “Effective Date”). In connection with Dr. Stephenson’s transition from the Company, pursuant to and subject to the terms of the employment offer letter agreement, dated October 26, 2018, as amended on February 2…
Entry into a Material Definitive Agreement. Indenture and Notes On February 28, 2025, BridgeBio Pharma, Inc. (“BridgeBio”) issued an aggregate of $575.0 million aggregate principal amount of its 1.75% Convertible Senior Notes due 2031 (the “Notes”), pursuant to an Indenture dated February 28, 2025 (the “Indenture”), between BridgeBio and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), in a private offering to qualified institutional buyers (the “Note Offering”) purs…
Other Events. On February 24, 2025, BridgeBio issued a press release announcing its intention to offer the Notes. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. On February 25, 2025, BridgeBio issued a press release announcing the pricing of the Notes . A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. Share Repurchases BridgeBio used approximately $48.3 million of the net proceeds from th…
Creation of a Direct Financial Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information provided in
BridgeBio used a portion of the net proceeds from the Note Offering to repay all outstanding borrowings under the Financing Agreement and pay any related fees thereto. The Financing Agreement was terminated on February 28, 2025.
BridgeBio’s offering and sale of the Notes to the Initial Purchasers was made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act. BridgeBio relied on this exemption from registration based in part on representations made by the Initial Purchasers in the purchase agreement for the Notes, including that the Initial Purchasers would only offer, sell or deliver the Notes to persons whom they believed to be qualified institutional buyers within the mea…
Results of Operations and Financial Condition. On February 20, 2025, BridgeBio Pharma, Inc. reported recent business updates and its financial results for the fourth quarter and full year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.